About Ambit Biosciences (NASDAQ:AMBI)
Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company's lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company's second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company's third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Ambit Biosciences (NASDAQ:AMBI) Frequently Asked Questions
What is Ambit Biosciences' stock symbol?
Ambit Biosciences trades on the NASDAQ under the ticker symbol "AMBI."
How were Ambit Biosciences' earnings last quarter?
Ambit Biosciences Corp (NASDAQ:AMBI) announced its quarterly earnings data on Tuesday, May, 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by $0.03. The biopharmaceutical company earned $0.03 million during the quarter, compared to analysts' expectations of $3.50 million. View Ambit Biosciences' Earnings History.
Who are some of Ambit Biosciences' key competitors?
Some companies that are related to Ambit Biosciences include Biogen (BIIB), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Abcam (ABC), Auxilium Pharmaceuticals (AUXL), Horizon Therapeutics (HPTX), Anika Therapeutics (ANIK), Myovant Sciences (MYOV), Vitae Pharmaceuticals (VTAE), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Kadmon (KDMN), 3SBio (SSRX), Strongbridge Biopharma (SBBP), Syros Pharmaceuticals (SYRS), Syndax Pharmaceuticals (SNDX), Kamada (KMDA) and Mereo BioPharma Group (MPH).
How do I buy Ambit Biosciences stock?
Shares of Ambit Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Ambit Biosciences?
Ambit Biosciences' mailing address is 11080 Roselle St, SAN DIEGO, CA 92121-1233, United States. The biopharmaceutical company can be reached via phone at +1-858-3342100.
MarketBeat Community Rating for Ambit Biosciences (AMBI)MarketBeat's community ratings are surveys of what our community members think about Ambit Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ambit Biosciences (NASDAQ:AMBI) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Ambit Biosciences (NASDAQ:AMBI) Earnings History and Estimates Chart
Ambit Biosciences (NASDAQ AMBI) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/12/2014||Q2 2014||($0.58)||($0.68)||$0.03 million||$0.03 million||View||Listen|
|5/6/2014||Q1||($0.47)||($0.50)||$3.50 million||$0.03 million||View||Listen|
Ambit Biosciences (NASDAQ:AMBI) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Ambit Biosciences (NASDAQ:AMBI)
No dividend announcements for this company have been tracked by MarketBeat.com
Ambit Biosciences (NASDAQ AMBI) News Headlines
Ambit Biosciences (NASDAQ:AMBI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ambit Biosciences (NASDAQ:AMBI) Income Statement, Balance Sheet and Cash Flow Statement
Ambit Biosciences (NASDAQ AMBI) Stock Chart for Friday, January, 19, 2018